FDA Advisers Back Full Approval of Paxlovid

Published on March 16, 2023

It’s official folks, the renowned FDA advisers have given their resounding seal of approval to Pfizer’s oral antiviral treatment, Paxlovid, for adults at high risk of progressing to severe COVID-19. Think of it like having a superhero sidekick on your journey to fighting off the virus! These brilliant minds voted with an overwhelming majority (16-to-1) in favor of granting full approval. This is a game-changer, as it means Paxlovid could soon be more readily available for those who need it most. Now, imagine this: when you’re feeling under the weather, you don’t just hunker down in bed and hope for the best – you get up, put on your cape, and equip yourself with everything you need to conquer the illness head-on! Full approval of Paxlovid gives patients and healthcare professionals another powerful tool to combat the virus and reduce the risk of severe disease. To delve deeper into the details of this exciting development and learn more about Paxlovid’s potential impact, check out the full article!

Advisers to the U.S. Food and Drug Administration on Thursday overwhelmingly backed Pfizer’s oral antiviral COVID-19 treatment Paxlovid for full approval in adults at high risk of progression to severe disease. The FDA’s panel of outside experts voted 16-to-1 in favor of the…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>